p21 (CDKN1A) Rabbit Polyclonal Antibody

CAT#: TA327053

CDKN1A Rabbit Polyclonal Antibody

Product Images

Western blot analysis of extracts of various cell lines, using CDKN1A antibody.

• 

  Immunofluorescence analysis of MCF7 cell using CDKN1A antibody. Blue: DAPI for nuclear staining.

Specifications

Product Data

• Applications: ICC/IF, WB
• Recommended Dilution: WB 1:500 - 1:2000;IF 1:50 - 1:200
• Reactivities: Human, Mouse, Rat
• Host: Rabbit
• Isotype: IgG
• Clonality: Polyclonal
• Immunogen: Recombinant protein of human CDKN1A
• Formulation: Store at -20C or -80C. Avoid freeze / thaw cycles. Buffer: PBS with 0.02% sodium azide, 50% glycerol, pH7.3
• Concentration: lot specific
• Purification: Affinity purification
• Conjugation: Unconjugated
• Storage: Store at -20°C as received.
• Stability: Stable for 12 months from date of receipt.
• Gene Name: cyclin-dependent kinase inhibitor 1A
• Database Link:
  NP_510867
  Entrez Gene 12575 MouseEntrez Gene 114851 RatEntrez Gene 1026 Human
  UniProt ID P38936
• Background: The tumor suppressor protein p21 Waf1/Cip1 acts as an inhibitor of cell cycle progression. It functions in stoichiometric relationships forming heterotrimeric complexes with cyclins and cyclin-dependent kinases. In association with CDK2 complexes, it serves to inhibit kinase activity and block progression through G1/S. However, p21 may also enhance assembly and activity in complexes of CDK4 or CDK6 and cyclin D. The carboxy-terminal region of p21 is sufficient to bind and inhibit PCNA, a subunit of DNA polymerase, and may coordinate DNA replication with cell cycle progression. Upon UV damage or during cell cycle stages when cdc2/cyclin B or CDK2/cyclin A is active, p53 is phosphorylated and upregulates p21 transcription via a p53-responsive element. Protein levels of p21 are downregulated through ubiquitination and proteasomal degradation.
• Synonyms: CAP20; CDKN1; CIP1; MDA-6; P21; p21CIP1; SDI1; WAF1

Reference Data

• Protein Families: Druggable Genome
• Protein Pathways: Bladder cancer, Cell cycle, Chronic myeloid leukemia, ErbB signaling pathway, Glioma, Melanoma, p53 signaling pathway, Pathways in cancer, Prostate cancer